{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wagemann O"],"funding":["NCATS NIH HHS","NIA NIH HHS","NIMH NIH HHS"],"pagination":["582-593"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11059071"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(6)"],"pubmed_abstract":["<h4>Importance</h4>Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).<h4>Objective</h4>To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment.<h4>Design, setting, and participants</h4>From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted"],"journal":["JAMA neurology"],"pubmed_title":["Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial."],"pmcid":["PMC11059071"],"funding_grant_id":["P30 AG066530","R56 AG053267","U01 AG079850","UL1 TR001863","U01 AG042791","R01 AG046179","P30 AG062429","R01 AG053267","R01 AG062268","R01 MH120794"],"pubmed_authors":["Fox NC","Brooks WS","Dominantly Inherited Alzheimer Network–Trials Unit","Shi X","Scelsi MA","Stauber J","Wagemann O","Nicklaus J","Laske C","Masters C","Coalier KA","Mummery CJ","Herries E","Okhravi HR","Allegri RF","Daniels AJ","Xu J","Ramirez L","Gordon BA","Cruchaga C","Martins R","Lah JJ","Xu X","Cash DM","Johnson ECB","Chhatwal J","Marsh J","Hornbeck R","Salloway S","McKay N","Proctor NK","Courtney L","Sims JR","Roberson ED","Gremminger E","Koudelis D","Supnet-Bell C","Massoumzadeh P","Huey ED","Jerome G","Ryan NS","Mendez PC","Keefe S","Perrin RJ","Simmons A","Kuder-Buletta E","Vоglein J","Rosa-Neto P","Ikeuchi T","Holtzman DM","Aguillon D","Ikonomovic S","Schofield PR","Barthelemy N","McCullough A","Hassenstab JJ","Hofmann A","Jucker M","Yaari R","Rizzo J","Gauthier S","Noble JM","Farlow MR","Day GS","Fagan AM","Nadkarni NK","Wang G","Bateman RJ","Bechara JA","Roedenbeck Y","Graff-Radford NR","Niimi Y","Berman SB","Baker B","Graber-Sultan S","Obermueller U","Seyfried NT","Wang Q","Galasko D","Karch CM","van Dyck CH","Llibre-Guerra J","Ringman JM","Lee JH","Chen C","Li Y","Chen A","Picarello DM","Flores S","Xiong C","Minton M","Renton AE","Pariente J","Lu R","Liu H","Hsiung GR","Franklin E","Holdridge KC","Bittner T","Suzuki K","Stout S","Scott J","Kasuga K","Mori H","Pulizos C","Ibanez L","St George-Hyslop P","Goate AM","Jackson K","Vazquez S","Clifford DB","Joseph-Mathurin N","Levey AI","Smith H","Roh JH","McDade E","Morris JC","Sabaredzovic E","Smith J","Aschenbrenner AJ","Levin J","Surace E","Santacruz AM","Mancini M","Sanchez-Valle R","Andersen SW","Jarman S","Benzinger TLS","Lopera F","Leon YM"],"additional_accession":[]},"is_claimable":false,"name":"Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.","description":"<h4>Importance</h4>Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).<h4>Objective</h4>To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment.<h4>Design, setting, and participants</h4>From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-01T09:23:40.549Z","creation":"2026-04-08T11:12:07.552Z"},"accession":"S-EPMC11059071","cross_references":{"pubmed":["38683602"],"doi":["10.1001/jamaneurol.2024.0991"]}}